Glucagon-like peptide-1 receptor agonist use is associated with higher severity of acute pancreatitis

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for obesity, type 2 diabetes, and MASLD. Although an association with pancreatitis has been reported, the clinical features, severity, and course of acute pancreatitis in patients receiving GLP-1RA therapy remain poorly characterized. We aimed to compare pancreatitis severity and outcomes in patients with and without GLP-1RA exposure. METHODS: We conducted a retrospective cohort study of patients admitted with acute pancreatitis from March 2017 to August 2024. Patients were stratified by GLP-1RA exposure for at least 3 months prior to diagnosis. The primary outcome was disease severity measured by the Bedside Index for Severity in Acute Pancreatitis (BISAP). Secondary outcomes included liver biochemical abnormalities (AST, ALT, ALP, bilirubin), imaging findings, clinical complications, length of stay, and post-pancreatitis sequelae. An exploratory analysis compared biliary pathology (gallstones, choledocholithiasis, or biliary sludge) between GLP-1RA users with antecedent weight loss and patients with prior bariatric surgery. RESULTS: Among 149 patients, 49 (32.9%) were receiving a GLP-1RA. In adjusted analysis, GLP-1RA use was independently associated with a BISAP score ≥ 2 (OR 5.25, 95% CI 1.13-24.34, p = 0.034), and increasing age was also associated with higher severity (OR 1.07, 95% CI 1.03-1.12, p = 0.001). GLP-1RA users had higher rates of pancreatitis-associated ascites but lower rates of new-onset diabetes and exocrine pancreatic insufficiency, with no significant differences in other clinical outcomes. GLP-1RA users exhibited greater antecedent weight loss (p < 0.001), but biliary pathology did not differ significantly between groups. CONCLUSIONS: GLP-1RA use was associated with higher predicted severity of pancreatitis at presentation, reflected by a greater probability of a BISAP score ≥ 2, without a corresponding increase in post-pancreatitis complications. Nearly, half of GLP-1RA users developed pancreatitis within 1 year of therapy initiation. Most experienced antecedent weight loss, raising concern for a biliary contribution, although biliary pathology was observed both with the gallbladder in situ and after prior cholecystectomy.

Authors

Institutions

Publication Details

Journal
Surgical Endoscopy
Published
2026-11-17
DOI
https://doi.org/10.1007/s00464-026-13472-3
Primary Topic
Pancreatitis Pathology and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Glucagon-like peptide-1 receptor agonist use is associated with higher severity of acute pancreatitis

Anwesh Dash, Sarjukumar Panchal, Esteban Urias, Dilara Hatipoğlu et al.
5 links
Surgical Endoscopy
Pancreatitis Pathology and Treatment
article

Glucagon-like peptide-1 receptor agonist use is associated with higher severity of acute pancreatitis

Anwesh Dash, Sarjukumar Panchal, Esteban Urias, Dilara Hatipoğlu, Michael L. Kochman, Emily Ertmann, Van Anh Tran, Veena Madhu
article en

Abstract

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for obesity, type 2 diabetes, and MASLD. Although an association with pancreatitis has been reported, the clinical features, severity, and course of acute pancreatitis in patients receiving GLP-1RA therapy remain poorly characterized. We aimed to compare pancreatitis severity and outcomes in patients with and without GLP-1RA exposure. METHODS: We conducted a retrospective cohort study of patients admitted with acute pancreatitis from March 2017 to August 2024. Patients were stratified by GLP-1RA exposure for at least 3 months prior to diagnosis. The primary outcome was disease severity measured by the Bedside Index for Severity in Acute Pancreatitis (BISAP). Secondary outcomes included liver biochemical abnormalities (AST, ALT, ALP, bilirubin), imaging findings, clinical complications, length of stay, and post-pancreatitis sequelae. An exploratory analysis compared biliary pathology (gallstones, choledocholithiasis, or biliary sludge) between GLP-1RA users with antecedent weight loss and patients with prior bariatric surgery. RESULTS: Among 149 patients, 49 (32.9%) were receiving a GLP-1RA. In adjusted analysis, GLP-1RA use was independently associated with a BISAP score ≥ 2 (OR 5.25, 95% CI 1.13-24.34, p = 0.034), and increasing age was also associated with higher severity (OR 1.07, 95% CI 1.03-1.12, p = 0.001). GLP-1RA users had higher rates of pancreatitis-associated ascites but lower rates of new-onset diabetes and exocrine pancreatic insufficiency, with no significant differences in other clinical outcomes. GLP-1RA users exhibited greater antecedent weight loss (p < 0.001), but biliary pathology did not differ significantly between groups. CONCLUSIONS: GLP-1RA use was associated with higher predicted severity of pancreatitis at presentation, reflected by a greater probability of a BISAP score ≥ 2, without a corresponding increase in post-pancreatitis complications. Nearly, half of GLP-1RA users developed pancreatitis within 1 year of therapy initiation. Most experienced antecedent weight loss, raising concern for a biliary contribution, although biliary pathology was observed both with the gallbladder in situ and after prior cholecystectomy.

Surgical Endoscopy
University of Pennsylvania (US)
Good health and well-being
Pancreatitis Pathology and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon